SpaceX investors are finally getting some reprieve after months of being whipsawed by volatility as the Elon Musk-led company’s stock breaks above the level it’s been stuck below since July.
Silver Range has granted Resilience an option to acquire an 80% interest in the Sand Springs mining property (the "Sand Springs Property"), located in Churchill County, Nevada, U.S.A. Resilience can ...
TFP Group’s forward strategy focuses on organic growth, but rising costs, key partner concentration, and key man risk remain ...
STORY: Never before has so much money been poured into a new technology as is now flowing into AI. Not for the internet, not for electrification, not even for the railways. So here's the question: ...
Neutral Holdings stands out as a unique, scaled micromobility provider with strong growth potential. Click here to find out ...
DayOne targets mid-October roadshow and November debut, sources say Investors favor operators with broader customer bases and clearer demand visibility SoftBank-backed SB Energy delays IPO amid ...
On September 23, 2026, the Kenyan supermarket chain Quickmart announced its plan to list on the Nairobi Securities Exchange (NSE).Existing shareholders will sell half of their holdings to investors, ...
When British neocloud Nscale goes public, it will test public investors’ appetite for a stock whose revenue is tied primarily to two customers. Since it was spun out of Australian cryptocurrency ...
Anthropic plans to stage its blockbuster initial public offering in November, later than many investors expected, as leaders of the biggest companies in the artificial-intelligence race call for a ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Most CEOs spend the weeks before an initial public offering pitching investors, strategizing with bankers, and putting the final touches on their IPO prospectus. Anthropic’s Dario Amodei has spent ...
Electra expects to spend $220 million to advance ipsoprubart through a phase 2/3 global study in secondary hemophagocytic lymphohistiocytosis. (iStock / Getty Images Plus) Electra Therapeutics is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results